Press releases

Company moves up Q3 earnings release date

TAXUS® Atom™ in more than 500 accounts Company opening new PROMUS™ accounts

Joint efforts will focus on intravascular ultrasound (IVUS)

Thursday and Friday of last week saw continued heavy trading in Boston Scientific's (NYSE: BSX) stock. As anticipated in the Company's October 9th...

Two-year pooled ARRIVE data showed the TAXUS Stent reduced clinical restenosis in patients with diabetes as effectively as in patients without diabetes

New coronary stent features thin struts designed for more uniform drug delivery

TAXUS Liberte drug eluting stent, launched in Europe and other international markets in 2005, to launch in U.S. next month

Company will also present results from the ARRIVE diabetic subset analysis, the ATLAS Workhorse and Direct Stenting trials and ATLAS data on small vessels and long lesions

The recent turmoil in the financial markets and bankruptcy of Lehman Brothers triggered automatic share selling

Company to discuss these and other issues on its third quarter earnings call on October 23 at 8:00 a.m.

PERSEUS clinical program to evaluate TAXUS® Element™ Platinum Chromium Stent

Judgment against Company entered in a patent case filed in 1997; Company to appeal

Company also announces FDA approval of TAXUS® Express2™ Stent System for treatment of in-stent restenosis

A live webcast and replay of the September 25 session will be available

Boston Scientific Corporation (NYSE: BSX) announced today a decision by the United States District Court in Delaware. The case involves a patent...

A live webcast and replay of the Tuesday, September 16 session will be available

Company announced positive one-year results from the world's largest post-approval, prospective registry for a single drug-eluting stent (DES)

Overall results demonstrated no statistically significant differences between PCI and CABG in rates of death or myocardial infarction (MI)

Boston Scientific obligation reduced from $250 to $19 million; Company to appeal remaining award

Company to present data from landmark SYNTAX clinical trial

"We were pleased with the quarter, especially with our expense management and working capital initiatives,” said CEO Jim Tobin.

Boston Scientific only company to offer choice of two distinct drugs on separate drug-eluting stent platforms

A live webcast and replay of the July 22 conference call will be available

Legislation would help service veterans and the active armed forces better manage the challenges of chronic pain

Transactions further Company's plans to focus on core businesses and increase shareholder value